2024 年至 2031 年生物银行市场类型、应用、样本类型和地区

生物库市场评估，2024-2031

基因组学、个人化医疗和生物技术日益重要，推动了对用于研发的高品质生物样本的需求。慢性病的增加，加上个人化医疗需求的不断增长，推动了对生物库的需求。此外，公共和私营部门的资金增加、大型生物库的建立以及储存和保存技术的进步也促进了市场的成长。此外，将生物库与大数据和人工智慧结合，以实现更有效的数据分析和利用，也对于产业的发展至关重要。预计生物银行市场收入将在 2023 年超过 10.6546 亿美元，到 2031 年将达到 21.1762 亿美元。

此外，现代生物库越来越多地使用自动化和数位化来提高样本收集、储存和资料管理的效率。冷冻保存和分子生物学程序的进步提高了保存的生物资源的品质和耐久性。此外，生物资讯学和数据分析的改进使得生物库样本能够更有效地用于研究和临床应用。确保道德标准和资料保护的监管框架也在不断发展，从而增加了社会对生物银行工作的信任和参与。预计 2024 年至 2031 年期间市场复合年增长率为 9.89%。

生物库市场定义/概述

现代生物库越来越多地使用自动化和数位化来提高样本收集、储存和资料管理的效率。冷冻保存和分子生物学程序的进步提高了保存的生物资源的品质和耐久性。此外，生物资讯学和数据分析的改进使得生物库样本能够更有效地用于研究和临床应用。确保道德标准和资料保护的监管框架也在不断发展，从而增加了社会对生物银行工作的信任和参与。这种情况的融合使得生物库成为改善科学研究和医疗保健结果的关键组成部分。生物库的未来潜力是巨大的和变革性的，对个人化医疗、遗传学和公共卫生具有重要意义。随着生物库的扩大，它们可以透过提供高品质、多样化的生物样整体支持大规模研究项目，从而更深入地瞭解疾病机制、基因突变和治疗反应。整合人工智慧和大数据分析等新技术将提高我们检测生物标记和设计标靶治疗的能力。此外，生物库可以促进国际合作，加强疾病监测，有助于预防性保健措施，并提供更有效和个人化的医疗介入。

基因体学和精准医疗的进步是否会导致生物库市场的成长？

基因组学和精准医疗的不断进步将极大地推动生物银行市场的扩张。基因组学和精准医疗依赖高品质的生物样整体更好地瞭解基因变异及其对健康和疾病的影响。生物库提供了储存和管理这些样本的必要基础设施，使其可用于研究和治疗。

标靶治疗的开发旨在根据特定的基因特征制定治疗方案。需要对疾病的遗传基础进行广泛的研究，这需要获取生物库中储存的大量且特征明确的生物样本。随着越来越多定製药物的开发，对生物库服务的需求正在增加。下一代定序（NGS）和其他基因组技术等定序技术的进步大大降低了基因分析的成本和时间。这些技术产生的大量数据必须与正确註释的生物样本连结。生物库在这过程中发挥关键作用，因为它们提供了大规模基因组研究所需的样本和数据。

此外，生物库透过提供来自不同人群的大量队列样本，促进了基因组研究和疾病知识的进步。这种支持对于确定疾病的遗传基础、发现生物标记和创建预测模型至关重要。随着基因组研究的扩展，强大的生物库基础设施变得越来越重要。精准医疗需要将基因组数据与临床资讯结合，才能全面瞭解患者的健康状况。生物库经常将生物样本与临床数据联繫起来，使研究人员能够将遗传资讯与健康结果关联起来。这种整合对于制定客製化治疗方案至关重要，从而增加了对生物银行服务的需求。

此外，基因组学和精准医学的进步经常需要监管和道德支持。改进的监管和道德框架将确保生物样本得到适当的收集、储存和使用。这样的框架将提高社会对生物库的信任和参与度，扩大可用的样本库，并加强市场。专注于基因组学和精准医疗的全球研究合作和联盟经常使用生物库来促进协作、数据共享和彙集资源。这种合作使得大规模研究和快速发现成为可能，增加了改善生物银行系统的需求。癌症、糖尿病和心血管疾病等慢性病的发生率不断上升，凸显了对大量生物库的需求，以便研究和开发新的治疗方法。个人化医疗主要依赖遗传和分子数据，这需要组织良好的生物库来提供必要的生物材料。

人们对基因组学和精准医疗的兴趣日益浓厚，刺激了商业和研究机构的大量投资。这项投资支持生物库设施的创建和发展，确保它们配备最新的技术和最佳实践，以满足该行业不断变化的需求。

样本品质和标准化是否会阻碍生物银行市场的发展？

不可重复的发现可能是由于样本品质差，破坏了科学研究的可靠性。如果样本在采集、处理或储存过程中受到污染、损坏或管理不善，实验结果可能会变得不一致和有偏差，使其他研究人员难以重现结果。样本品质的降低会损害连结资料的完整性，包括临床、基因组和组学资料。不准确或不完整的数据，加上样本品质差，会导致错误的结论并阻碍科学知识的进步。

此外，生物库的任务是长期（可能长达数十年）保存样本，因此必须确保样本随时间的完整性和稳定性。必须严格控制温度、湿度和光照等储存参数，以确保样品保持活力并代表原始样本。未能保持适当的储存条件可能会导致样品变质不适合下游分析。不同生物库所采用的程序、协议和设备的差异可能导致样本品质的差异，从而难以比较不同研究的结果和总结数据。

此外，监管合规和认证是生物银行的重要组成部分，生物银行必须遵守监管限制和认证标准，以确保其遵循道德、法律和品质保证规范。非标准化流程可能难以满足监管标准和认证，从而限制资金前景和与其他研究机构的合作。然而，由于品质问题或样本处理不一致而导致的明确特征的样本短缺可能会阻碍研究，尤其是针对罕见疾病或特定患者群体的研究。生物库的成功取决于维持利害关係人的信任，包括捐赠者、研究人员、医生和监管机构。样本品质差和缺乏统一性会降低人们对生物库资源的可靠性和实用性的信心，从而导致参与度、资金和支持的减少。

不同的收集技术可能会导致生物库内的样本品质变化，甚至同一生物库内的样本品质也会随时间而变化。标本处理、储存条件和处理步骤都会影响生物标本的完整性。维护标本元资料的准确和完整记录，包括收集细节、储存条件和品质控制参数，对于资料完整性和可追溯性至关重要。然而，人工记录程序和资料输入错误可能会危及标本资料的准确性。为了保持数据的准确性和可比性，重要的是拥有经过批准的参考材料和标准来验证分析方法和监测分析性能。然而，无法获得经过良好表征的参考材料可能会阻碍标准化样品品质评估和校准协议的努力。

目录

第 1 章 全球生物样本库市场简介

• 市场介绍
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章全球生物库市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第 5 章。

• 概述
• 设备
• 消耗品
• 服务
• 软体

6. 全球生物库市场（按应用）

• 概述
• 生命科学研究
• 再生医学
• 临床研究
• 治疗用途

7. 全球生物库市场（依样本型态）

• 概述
• 血液製品
• 人体组织
• 核酸
• 细胞系
• 生物体液
• 人类排泄物

第 8 章。

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚洲地区太平洋
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章。

• 概述
• 各公司的市场排名
• 主要发展策略

第十章 公司简介

• Tecan Group Ltd
• Lonza
• PHC Holdings Corporation
• Thermo Fisher Scientific Inc.
• Hamilton
• Brooks Automation
• Qiagen N.V.
• TTP Labtech Ltd
• Cryoport, Inc.
• Azenta, Inc.

第 11 章附录

• 相关研究

Biobanking Market Valuation - 2024-2031

The rising importance of genomics, personalized medicine, and biotechnology has raised the demand for high-quality biological samples, which are required for research and development. The rise in chronic diseases, combined with the growing need for personalized medicines, has increased the demand for biobanking. Furthermore, increased funding from both the public and commercial sectors, as well as the formation of large-scale biobanks and advances in storage and preservation technology, have all contributed to the market's growth. The integration of biobanking with big data and artificial intelligence for more effective data analysis and usage is also critical to the industry's growth. The Biobanking Market is expected to surpass a revenue of USD 1065.46 Million in 2023 and reach USD 2117.62 Million by 2031.

Furthermore, Modern biobanks incorporate enhanced automation and digitization to improve the efficiency of sample collection, storage, and data management. Cryopreservation and molecular biology procedures have advanced, improving the quality and endurance of stored biological resources. Furthermore, improved bioinformatics and data analytics enable more effective use of biobanked samples for research and clinical applications. Regulatory frameworks have also evolved to ensure ethical standards and data protection, resulting in increased public trust and participation in biobanking efforts. The market is expected to rise with a projectedCAGR of 9.89% from 2024 to 2031.

Biobanking Market: Definition/ Overview

Modern biobanks incorporate enhanced automation and digitization to improve the efficiency of sample collection, storage, and data management. Cryopreservation and molecular biology procedures have advanced, improving the quality and endurance of stored biological resources. Furthermore, improved bioinformatics and data analytics enable more effective use of biobanked samples for research and clinical applications. Regulatory frameworks have also evolved to ensure ethical standards and data protection, resulting in increased public trust and participation in biobanking efforts. This convergence of circumstances establishes biobanking as a critical component in increasing scientific research and healthcare outcomes. Biobanking's future potential is immense and transformational, with significant implications for personalized medicine, genetics, and public health. As biobanks expand, they will increasingly support large-scale research projects by supplying high-quality, diverse biological samples that allow for deeper insights into disease mechanisms, genetic variations, and therapeutic responses. Integration of new technologies such as artificial intelligence and big data analytics will improve the ability to detect biomarkers and design targeted treatments. Furthermore, biobanking can promote global cooperation, increase illness surveillance, and contribute to preventive healthcare measures, resulting in more effective and personalized medical interventions.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Increasing Advancements in Genomics and Precision Medicine Lead the Expansion of the Biobanking Market?

The increasing advancements in genomics and precision medicine significantly drive the expansion of the Biobanking Market. Genomics and precision medicine rely on high-quality biological samples to better understand genetic variants and their consequences for health and illness. Biobanks provide the required infrastructure to store and maintain these samples, making them available for research and therapeutic uses.

The development of targeted therapeutics aims to customize treatments to particular genetic profiles. Extensive research into the genetic basis of diseases is necessary, which is dependent on access to a broad and well-characterized set of biological samples held in biobanks. As more tailored medicines are created, the demand for biobanking services is increasing. Advances in sequencing technologies, such as next-generation sequencing (NGS) and other genomic technologies, have significantly lowered the cost and duration of genetic analysis. Massive amounts of data generated by these technologies must be linked to properly annotated biological samples. Biobanks play an important part in this process because they provide the samples and data required for large-scale genomic studies.

Furthermore, biobanks enhance genomic research and disease knowledge by providing access to large cohorts of samples from a variety of populations. This assistance is critical for determining the genetic basis of diseases, finding biomarkers, and creating predictive models. As genomic research expands, a strong biobanking infrastructure becomes increasingly important. Precision medicine requires the integration of genomic data and clinical information to provide full insights into patient health. Biobanks frequently link biological samples to clinical data, allowing researchers to correlate genetic information with health outcomes. This integration is critical for the development of tailored treatment programs, which increases demand for biobanking services.

Additionally, advances in genomes and precision medicine frequently require regulatory and ethical support. Improved regulatory and ethical frameworks ensure that biological samples are collected, stored, and used appropriately. These frameworks improve public trust and involvement in biobanking, which expands the available sample pool and strengthens the market. Global collaborations and consortia focused on genomics and precision medicine make collaboration and data sharing easier, and they frequently rely on biobanks to share resources. These joint efforts enable large-scale investigations and rapid discoveries, which increases the demand for improved biobanking systems. The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular ailments highlights the need for broad biobanking to enable research and development of new treatments. The change to customized medicine, which is primarily reliant on genetic and molecular data, demands well-maintained biobanks to supply the essential biological materials.

The increased interest in genomes and precision medicine has prompted significant investment from both commercial and research institutions. This investment supports the creation and growth of biobanking facilities, ensuring that they are equipped with the most up-to-date technologies and best practices to suit the field's evolving demands.

How does Sample Quality and Standardization Hold Back the Biobanking Market?

Irreproducible research findings might be the result of poor sample quality, weakening the credibility of scientific study. Variability and bias in experimental results can occur when samples are contaminated, damaged, or mismanaged during collection, processing, or storage, making it difficult for other researchers to duplicate the findings. Poor sample quality has the potential to jeopardize the integrity of linked data, including clinical, genomic, and omics data. Inaccurate or incomplete data combined with low-quality samples can lead to incorrect conclusions, impeding the growth of scientific knowledge.

Furthermore, biobanks must ensure sample integrity and stability throughout time, as they are tasked with storing samples for extended periods of time, perhaps decades. To guarantee that samples remain viable and representative of the original specimen, storage parameters must be strictly controlled, such as temperature, humidity, and light exposure. Failure to maintain correct storage conditions might cause sample degradation, making them unsuitable for downstream analysis. Inter-laboratory variability might result from a lack of standardization in sample collecting and processing techniques amongst biobanks. variations in the procedures, protocols, and equipment employed by different biobanks might cause variations in sample quality, making it difficult to compare results or combine data from various research.

Additionally, regulatory compliance and accreditation are critical parts of biobanking, with biobanks subject to regulatory restrictions and accrediting standards to ensure they follow ethical, legal, and quality assurance norms. Non-standardized processes might make it difficult to meet regulatory standards and acquire accreditation, limiting funding prospects and collaborations with other research institutes. Researchers rely on biobanks to offer high-quality samples for their studies; yet a lack of well-characterized samples due to quality issues or discrepancies in sample processing might hamper research efforts, particularly for uncommon diseases or specific patient populations. The success of biobanking efforts is dependent on sustaining stakeholder trust, which includes donors, researchers, doctors, and regulatory agencies. Poor sample quality and lack of uniformity can reduce trust in the trustworthiness and utility of biobank resources, leading to decreasing participation, financing, and support.

Different collection techniques within biobanks, or even within the same biobank over time, might result in changes in sample quality. Sample handling, storage conditions, and processing processes all have an impact on biological specimen integrity. Maintaining accurate and thorough documentation of sample metadata, such as collection details, storage conditions, and quality control parameters, is critical for data integrity and traceability. However, human record-keeping procedures and data input errors can jeopardize the accuracy of sample data. The availability of approved reference materials and standards for validating analytical methods and monitoring assay performance is critical for maintaining data correctness and comparability. However, limited access to well-characterized reference materials can stymie efforts to standardize sample quality assessment and calibration protocols.

Category-Wise Acumens

How does the Increasing Demand for Clinical Research Advance the Growth of the Biobanking Market?

The increasing demand for clinical research is fuelling growth in the Biobanking Market. Biobanks serve an important role in precision medicine projects by allowing researchers access to large-scale collections of well-characterized clinical samples such as tissues, blood, and biological fluids, as well as accompanying clinical data. These resources allow for the identification of disease biomarkers, the classification of patient populations, and the development of targeted medicines, increasing the demand for high-quality clinical samples held in biobanks.

Biobanks facilitate biomarker development and validation in clinical research, which is critical for improving illness diagnosis, monitoring therapy efficacy, and predicting patient outcomes. Diverse patient samples are made available for biomarker identification and validation investigations, which helps to translate basic research discoveries into therapeutic applications. Furthermore, biobanks provide researchers and pharmaceutical companies with patient-derived samples for preclinical investigations and biomarker-driven clinical trials.

Furthermore, using well-characterized clinical samples from biobanks, researchers can assess the safety, efficacy, and pharmacokinetics of investigational drugs, identify patient subgroups likely to benefit from treatment, and optimize trial design, thereby improving drug development efficiency and accelerating approval timelines. Biobanks also enhance disease modelling and personalized medicine techniques by allowing researchers access to patient-derived samples to study disease mechanisms, identify therapeutic targets, and design patient-specific treatment regimens. Using human tissues, cell lines, and bodily fluids from biobanks, researchers can mimic disease phenotypes in vitro and test medication responses in patient-derived models, allowing for individualized treatment selection and optimization based on specific patient features.

Additionally, the growing demand for clinical research is driving increased collaboration across biobanks, research institutions, and healthcare organizations to improve data exchange, standardize research protocols, and stimulate cross-disciplinary partnerships. Using shared resources and expertise, researchers can get access to larger and more diversified sample collections, overcome resource constraints, and accelerate scientific discoveries, thereby increasing our understanding of disease pathophysiology and patient treatment. Biobanks follow regulatory criteria and quality assurance standards to assure the ethical collection, storage, and dissemination of clinical samples. Compliance with laws such as Good Clinical Practice (GCP) and the Health Insurance Portability and Accountability Act (HIPAA) boosts confidence among researchers, sponsors, and regulatory bodies, promoting the expansion of the biobanking sector.

The increased emphasis on personalized healthcare, which seeks to provide tailored medical treatments based on unique patient characteristics, increases the demand for high-quality clinical samples and molecular data. Biobanks allow researchers and doctors to examine patient-derived samples for genetic variants, biomarker profiles, and therapy responses, resulting in more accurate diagnoses and focused medicines. High-throughput sequencing, omics technologies, and bioinformatics tools have revolutionized clinical research and biomarker identification. Biobanks use these technologies to undertake extensive molecular profiling of patient samples, detect disease signs, and predict therapy responses, fostering innovation and growth in the biobanking industry.

Will the Rising Utilization Nucleic Acids and Cell Lines Drive the Growth of the Biobanking Market?

The rising utilization of nucleic acids and cell lines in various research and clinical applications is expected to drive the growth of the Biobanking Market. High-throughput sequencing technologies have brought genomic research into the modern era, allowing for complete examination of DNA and RNA materials. Nucleic acids extracted from biobank specimens provide valuable resources for large-scale genomic investigations aiming at understanding disease genetics, finding biomarkers, and discovering therapeutic targets. As genomic research expands, there will be a large increase in demand for high-quality nucleic acid samples from biobanks.

Furthermore, nucleic acid samples are critical in precision medicine initiatives because they allow for the detection of genetic variants linked to disease susceptibility, therapeutic response, and treatment outcomes. Biobanks provide researchers and clinicians with access to vast libraries of well-annotated nucleic acid samples, which enables population-based studies and individualized healthcare interventions. Biobanks aid liquid biopsy research by giving access to archived blood samples and other biological fluids gathered over time from people with cancer and other disorders. Well-characterized nucleic acid samples from biobanks speed up the development and validation of liquid biopsy assays for clinical usage. Cell lines produced from biobank specimens are valuable tools for researching cellular physiology, disease processes, and medication responses in vitro.

Additionally, advances in stem cell biology, genome editing, and tissue engineering have expanded the use of cell lines in regenerative medicine, drug discovery, and disease modelling. Biobanks are repositories of verified and quality-controlled cell lines that help researchers develop cell-based therapeutics for a variety of ailments. Cell lines produced from biobank specimens are commonly used in pharmaceutical research and development to screen drug candidates, investigate pharmacological mechanisms of action, and predict drug toxicity.

Biobanks provide researchers and drug developers with diverse cell line collections covering various tissue types, disease states, and genetic origins, thereby expediting drug development, lowering costs, and increasing preclinical model predictability. Cell lines are also used in regenerative medicine applications such cell treatment, tissue engineering, and organ transplantation. Biobanks are critical in producing stem cell lines, induced pluripotent stem cells (iPSCs), and other cell types for regenerative medicine research and therapeutic use. The ability to bank and disseminate well-characterized and quality-controlled cell lines is critical for improving regenerative medicine therapy, driving market growth in this segment.

Biobanking Market

Report Methodology

Country/Region-wise

How does Advanced Healthcare Infrastructure and Research Funding in North America Boost Up the Biobanking Market?

North America's advanced healthcare infrastructure and robust research funding and investment ecosystem create an enabling environment for biobanking activities. North America is distinguished by cutting-edge healthcare facilities, such as hospitals, clinics, and research institutions, which are outfitted with advanced diagnostic and treatment technologies, providing the infrastructure for conducting biomedical research and clinical studies that require access to patient samples.

The region's interconnected healthcare ecosystem promotes collaboration among healthcare providers, research institutions, and biobanks, allowing clinicians to easily collect and bank biospecimens from patients enrolled in clinical trials or routine healthcare visits. This agreement guarantees a consistent supply of high-quality samples for biobanking programs.

Furthermore, many healthcare organizations in North America have taken a patient-centric approach, encouraging patient participation in research activities, such as sample donation for biobanking purposes. Patient engagement initiatives, such as informed consent processes, community outreach programs, and patient advocacy groups, promote awareness of biobanking and facilitate sample collection efforts. The widespread adoption of electronic health records (EHR) in North America facilitates the integration of clinical and research data, streamlining sample collection and data annotation processes. Biobanks can leverage EHR systems to identify eligible patients, track sample provenance, and link molecular data with clinical outcomes, thereby enhancing the utility of biobank resources for research purposes.

Additionally, regarding research funding and investment, substantial funding is allocated by government agencies in North America, such as the National Institutes of Health (NIH) in the United States and the Canadian Institutes of Health Research (CIHR) in Canada, to support biomedical research and biobanking initiatives. These agencies' research grants and cooperative agreements make it possible to build and expand biobanks, fund infrastructure development, sample collection initiatives, and conduct research projects that use biobank resources. Furthermore, North America receives significant private funding from venture capital firms, philanthropic organizations, and biotechnology corporations interested in supporting biobanking infrastructure and research. Private investment enables biobanks to update their facilities, implement cutting-edge technology, and expand sample collections in response to new research objectives and market demands.

Collaboration between biobanks and pharmaceutical, biotechnology, and diagnostic industries in North America promotes innovation and speeds translational research initiatives. Industry partners may give financial support, technical experience, and access to specialized resources, thereby increasing the value proposition of biobank resources and accelerating the development of novel diagnostics, treatments, and personalized medicine strategies. Furthermore, collaboration between biobanks and academic institutions in North America encourages interdisciplinary research collaborations and knowledge sharing. Academic collaborations provide access to research skills, specialized equipment, and training opportunities, which improve biobank activities and advance scientific discovery in fields such as genomics, precision medicine, and regenerative therapies.

Will the Increasing Healthcare Expenditure and Growing Biotechnology in the Asia-Pacific Region Promote the Biobanking Market Further?

The increasing healthcare spending in the Asia-Pacific region enables investment in healthcare infrastructure, such as the establishment and expansion of biobanking facilities, which require sophisticated infrastructure for sample collection, processing, storage, and distribution, as well as specialised equipment and personnel. Higher healthcare spending allows for the development of cutting-edge biobanking infrastructure, hence supporting market growth.

Healthcare expenditure enables higher funding allocations for research and development (R&D) activities in the Asia-Pacific region, with academic institutions, research organizations, and pharmaceutical companies receiving more resources to conduct biomedical research, drug discovery, and clinical trials. Biobanks play an important role in supporting R&D operations by providing high-quality biological samples, hence generating demand for biobanking services and solutions. The growth of healthcare access in the Asia-Pacific area, driven by increased healthcare spending, creates a growing demand for healthcare solutions suited to individual patients' requirements, including personalized medicine approaches.

Furthermore, biobanks support personalized medicine initiatives by providing biological samples for genomic research, biomarker identification, and pharmaceutical development, which drives market demand. Government initiatives and policies in the Asia-Pacific region encourage healthcare innovation, research collaboration, and technological adoption, with many countries providing incentives and funding to support biobanking infrastructure development, research partnerships, and regulatory compliance. Initiatives like China's Precision Medicine Initiative and Singapore's Biomedical Sciences Initiative seek to improve healthcare innovation and research, hence promoting the expansion of the biobanking industry. Increased healthcare spending drives developments in healthcare services and technologies in the Asia-Pacific area. Precision medicine, genetic research, and personalized healthcare approaches are becoming increasingly popular, need access to large amounts of biological samples and data. Biobanks play an important role in allowing these advances by supplying broad and well-characterized sample sets, which drive market growth.

Additionally, emerging markets and potential in the Asia-Pacific area, such as China, India, and South Korea, are driven by increased healthcare expenditure, leading to demand for biobanking solutions and infrastructure. These countries, with their huge and diverse populations, genetic variety, and rising burden of chronic diseases, present enormous prospects for biobanking services and research collaborations. Biobanks serve a crucial role in drug discovery and development efforts by biotechnology companies in the Asia-Pacific area by giving access to varied biological samples. These activities include target identification, lead optimization, and preclinical testing.

Precision medicine projects in the Asia-Pacific area are highlighted, with the goal of tailoring medical therapies to individual patients' genetic makeup and illness profiles, with biobanks serving as critical resources for genomic analysis, biomarker development, and tailored treatment options. Biotechnology companies in Asia-Pacific are also looking into regenerative medicine approaches such as cell therapy, tissue engineering, and organ transplantation, with biobanks helping with research by providing stem cells, tissue samples, and other biological materials for experimentation and clinical applications.

Competitive Landscape

The Biobanking Market's competitive landscape includes a diversified mix of rising startups, specialty service providers, and regional biobanks. These firms frequently focus on specialized services, such as niche sample kinds, innovative storage systems, or specific disease regions, to meet the changing needs of researchers and pharmaceutical corporations. Furthermore, technical developments in sample processing, storage, and data management have resulted in the emergence of creative solution providers who offer unique platforms and services, upsetting established biobanking models. Regional biobanks, especially in emerging economies, add to the competitive landscape by leveraging local expertise, cooperation with academic institutions, and government backing to establish biobanking infrastructure suited to regional healthcare requirements.

Some of the prominent players operating in the Biobanking Market include:

Tecan Group Ltd, Lonza, PHC Holdings Corporation, Thermo Fisher Scientific Inc., Hamilton, Brooks Automation, Qiagen N.V., TTP Labtech Ltd, Becton, Dickinson and Company, Merck & Co., Avantor, Inc., Cryoport, Inc., Azenta, Inc.

Latest Developments

In April 2023, Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, in a deal intended to bolster the buyer's immunology drug pipeline as it faces loss of exclusivity for some of its best-selling products over the next few years. Based in San Diego, Prometheus develops precision drugs and companion diagnostics for immune-mediated diseases. The company's lead candidate, PRA023, is a humanized monoclonal antibody indicated for autoimmune conditions that include ulcerative colitis (UC), Crohn's disease (CD), and Systemic Sclerosis-associated Interstitial Lung Disease.

In October 2022, LabVantage Solutions and Biomax Informatics Merge to Create Innovative Capabilities for the Life Science and Bio Manufacturing Industries. LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, and Biomax Informatics AG, a software solutions and services provider for efficient decision-making and knowledge management at the intersection of life sciences, healthcare, and information technologies. Customers will now have more confidence in mission-critical projects that depend on the contextualisation of scientific data.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BIOBANKING MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BIOBANKING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BIOBANKING MARKET, BY TYPE

• 5.1 Overview
• 5.2 Equipment
• 5.3 Consumables
• 5.4 Services
• 5.5 Software

6 GLOBAL BIOBANKING MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Life Science Research
• 6.3 Regenerative Medicine
• 6.4 Clinical Research
• 6.5 Therapeutic Applications

7 GLOBAL BIOBANKING MARKET, BY SAMPLE TYPE

• 7.1 Overview
• 7.2 Blood Products
• 7.3 Human Tissues
• 7.4 Nucleic Acids
• 7.5 Cell Lines
• 7.6 Biological Fluids
• 7.7 Human Waste Products

8 GLOBAL BIOBANKING MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL BIOBANKING MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Tecan Group Ltd
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Lonza
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 PHC Holdings Corporation
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Thermo Fisher Scientific Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Hamilton
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Brooks Automation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Qiagen N.V.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 TTP Labtech Ltd
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Cryoport, Inc.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Azenta, Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research